Winston Pharmaceuticals, Inc.
Other OTCTotal Valuation
Winston Pharmaceuticals, Inc. carries a market capitalization of 7,741.00, placing it among publicly traded companies globally.
| Market Cap | 7,741.00 |
| Enterprise Value | N/A |
Share Statistics
Winston Pharmaceuticals, Inc. currently has 77.41M shares outstanding.
| Shares Outstanding | 77.41M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 46.07, and the price-to-book ratio stands at -1.27.
| PE Ratio | N/A |
| PS Ratio | 46.07 |
| PB Ratio | -1.27 |
| P/TBV Ratio | 1,354.73 |
| P/FCF Ratio | -17.84 |
| P/OCF Ratio | -17.83 |
Financial Position
Winston Pharmaceuticals, Inc. maintains a current ratio of 1.04, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.04 |
| Quick Ratio | 0.87 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -90.81 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Winston Pharmaceuticals, Inc.'s stock has declined approximately -66.66667% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -66.66667% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Winston Pharmaceuticals, Inc. generated 1.37M in revenue and converted that into -2.34M in net income, yielding earnings per share of -0.04. EBITDA reached -2.41M, while operating income came in at -2.41M.
| Revenue | 1.37M |
| Gross Profit | 1.37M |
| Operating Income | -2.41M |
| Pretax Income | -2.34M |
| Net Income | -2.34M |
| EBITDA | -2.41M |
| EBIT | -2.41M |
| Earnings Per Share (EPS) | -0.04 |
Balance Sheet
Total book value stands at -49.77M, with working capital of 34,260.00 providing operational flexibility.
| Cash & Cash Equivalents | 677,522.00 |
| Total Debt | N/A |
| Net Debt | -677,522.00 |
| Equity (Book Value) | -49.77M |
| Book Value Per Share | -0.79 |
| Working Capital | 34,260.00 |
Cash Flow
Winston Pharmaceuticals, Inc. produced -3.54M in operating cash flow over the past twelve months. After subtracting -2,174.00 in capital expenditures, free cash flow totaled -3.54M - equivalent to -0.06 per share.
| Operating Cash Flow | -3.54M |
| Capital Expenditures | -2,174.00 |
| Free Cash Flow | -3.54M |
| FCF Per Share | -0.06 |
Margins
Winston Pharmaceuticals, Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -176.05 and net profit margin of -170.44 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -176.05 |
| Pretax Margin | -170.44 |
| Profit Margin | -170.44 |
| EBITDA Margin | -175.40 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.08 |
| FCF Yield | -5.60 |
Stock Splits
Winston Pharmaceuticals, Inc.'s most recent stock split took place on January 16, 2009 with a 8:1 split ratio.
| Last Split Date | 1/16/2009 |
| Split Ratio | 8:1 |
Scores
Winston Pharmaceuticals, Inc. posts an Altman Z-Score of -43.89, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -43.89 |